Eligible CLL patients who sign an informed consent will be started on hydroxychloroquine
400mg po daily for up to one year. They will be monitored for disease status as well as
adverse reactions after two weeks and then every 4 weeks. Ophthalmologic exams is required at
baseline and every 6 months or sooner if the patient develops any visual disturbances.